These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 11283121

  • 1. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.
    Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J.
    J Clin Oncol; 2001 Apr 01; 19(7):1901-5. PubMed ID: 11283121
    [Abstract] [Full Text] [Related]

  • 2. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
    Wang Y, Herrstedt J, Havsteen H, DePoint Christensen R, Mirza MR, Lund B, Maenpaa J, Kristensen G.
    BMC Cancer; 2014 Dec 11; 14():937. PubMed ID: 25494701
    [Abstract] [Full Text] [Related]

  • 3. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
    Abaid LN, Micha JP, Rettenmaier MA, Brown JV, Mendivil AA, Lopez KL, Goldstein BH.
    Cancer Chemother Pharmacol; 2013 Jul 11; 72(1):101-7. PubMed ID: 23660691
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer.
    Arimoto T, Nakagawa S, Oda K, Kawana K, Yasugi T, Taketani Y.
    Med Oncol; 2012 Jun 11; 29(2):1253-4. PubMed ID: 21380784
    [Abstract] [Full Text] [Related]

  • 10. A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Gould N, Sill MW, Mannel RS, Thaker PH, DiSilvestro PA, Waggoner SE, Yamada SD, Armstrong DK, Fracasso PM, Walker JL.
    Gynecol Oncol; 2012 Dec 11; 127(3):506-10. PubMed ID: 22943879
    [Abstract] [Full Text] [Related]

  • 11. Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial.
    Markman M, Glass T, Smith HO, Hatch KD, Weiss GR, Taylor SA, Goodwin JW, Alberts DS.
    Gynecol Oncol; 2003 Mar 11; 88(3):282-8. PubMed ID: 12648576
    [Abstract] [Full Text] [Related]

  • 12. Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum.
    Markman M, Zanotti K, Webster K, Peterson G, Kulp B, Belinson J.
    Gynecol Oncol; 2003 Dec 11; 91(3):573-6. PubMed ID: 14675679
    [Abstract] [Full Text] [Related]

  • 13. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
    Clamp AR, James EC, McNeish IA, Dean A, Kim JW, O'Donnell DM, Hook J, Coyle C, Blagden S, Brenton JD, Naik R, Perren T, Sundar S, Cook AD, Gopalakrishnan GS, Gabra H, Lord R, Dark G, Earl HM, Hall M, Banerjee S, Glasspool RM, Jones R, Williams S, Swart AM, Stenning S, Parmar M, Kaplan R, Ledermann JA.
    Lancet; 2019 Dec 07; 394(10214):2084-2095. PubMed ID: 31791688
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
    du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO, Merger M, Harter P, AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium.
    Lancet Oncol; 2016 Jan 07; 17(1):78-89. PubMed ID: 26590673
    [Abstract] [Full Text] [Related]

  • 17. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
    Morgan RD, McNeish IA, Cook AD, James EC, Lord R, Dark G, Glasspool RM, Krell J, Parkinson C, Poole CJ, Hall M, Gallardo-Rincón D, Lockley M, Essapen S, Summers J, Anand A, Zachariah A, Williams S, Jones R, Scatchard K, Walther A, Kim JW, Sundar S, Jayson GC, Ledermann JA, Clamp AR.
    Lancet Oncol; 2021 Feb 07; 22(2):277-288. PubMed ID: 33357510
    [Abstract] [Full Text] [Related]

  • 18. Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group.
    Morgan MA, Darcy KM, Rose PG, DeGeest K, Bookman MA, Aikins JK, Sill MW, Mannel RS, Allievi C, Egorin MJ, Gynecologic Oncology Group.
    Gynecol Oncol; 2008 Sep 07; 110(3):329-35. PubMed ID: 18597837
    [Abstract] [Full Text] [Related]

  • 19. High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer-A Phase 2 Cohort Study.
    Bruchim I, Weeg N, Alpert Y, Sade D, Piura E, Fishman A.
    Int J Gynecol Cancer; 2016 May 07; 26(4):640-7. PubMed ID: 27101523
    [Abstract] [Full Text] [Related]

  • 20. Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.
    Micha JP, Goldstein BH, Rettenmaier MA, Mattison J, Graham C, Birk CL, Brown JV.
    Gynecol Oncol; 2004 Sep 07; 94(3):719-24. PubMed ID: 15350364
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.